WHO strongly advises against antibody treatments for COVID-19patients bmj_latest
Understanding the recommendationthe panel concluded that it is no longer applicable to covid-19 caused by the SARS-CoV-2 variants that are currently circulating globally. The panel surmised that the likelihood of covid-19 caused by former variants was extremely low and that, accordingly, evidence of sotrovimab’s clinical effectiveness for covid-19 was inexistent.
What are the side effects of fluvoxamine therapy in patients with non-severe covid-19 at risk of deteriorating?
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: